US FDA Classifies Recall Of Philips’ Respiratory Devices As Most Serious

Maryland (Reuters) The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of Dutch medical devices maker Philips’ respiratory machines as most serious, saying their use could lead to injuries or death.

The U.S. health regulator said the silicon foam used in some reworked ventilator models may separate from plastic backing due to adhesive failure and can reduce the air flow as well as cause debris contamination.

The company’s ventilators provide breathing assistance to both pediatric and adult patients.

The recall follows Philips’ move to call back millions of breathing devices and ventilators in June 2021 due to the potential of a foam part degrading and becoming toxic, possibly causing cancer.

Its subsidiary, Philips Respironics, had in December also recalled about 13,811 ventilators which were distributed between March 1, 2022 and Sept. 6, 2022.

Philips did not immediately respond to a Reuters request for comment on the impact from the recall.

There were 82 complaints till Jan. 4 and no reports of death or long-term injuries associated with the use of the product, the U.S. FDA said.

  • Related Posts

    PGIMS recalls drug amid probe into deaths

    The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths

    NPPA list brings little relief: No price cut for 25% cancer drugs

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    For Aakash Healthcare, Community People are Apples of its Eyes

    For Aakash Healthcare, Community People are Apples of its Eyes

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Yashoda Medicity: Baby takes a Giant Step in just One Year